Biodel replaces Linjeta with trade name VIAject

Biodel Inc. (Nasdaq: BIOD) announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's  most advanced product candidate.  The change follows FDA's review and acceptance of Linjeta™ as an alternative name for Biodel's more-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Application date of October 30, 2010.  

Dr. Errol De Souza, Biodel 's president and chief executive officer, stated: "Today's news reflects the continued progress of the Linjeta™ new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate."

Source:

Biodel Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post